Lonza and Eclipse Therapeutics Announce Development and Manufacturing Agreement for Lonza to Conduct Phase 1 Production of Eclipse’s ET-101

Lonza will manufacture ET-101 at its mammalian development and manufacturing facility in Slough, UK

06-Mar-2012 - Switzerland

Lonza and Eclipse announced an agreement for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Light Path™ Development Services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Under the agreement, Lonza will produce phase 1 clinical material at its development and manufacturing facility in Slough, UK.

Cancer stem cells are a small subset of cells within a tumor that are thought to play a critical role in tumor initiation, recurrence and metastasis. ET-101 is a novel therapeutic antibody designed to target these cancer stem cells. Eliminating cancer stem cells, in conjunction with other therapies that address the tumor bulk, represents a new cancer treatment paradigm that could offer a distinct advantage over existing strategies and a solution for chemoresistance.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances